Fora Capital, LLC Blueprint Medicines Corp Transaction History

Fora Capital, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$43.96 - $92.84 $1.07 Million - $2.26 Million	24,306 New	24,306 $2.24 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $159,027 - $247,474	3,185 New	3,185 $210,000
Q1 2022 May 12, 2022	SELL	$54.1 - $110.08 $150,019 - $305,251	-2,773 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$94.25 - $115.99 $261,355 - $321,640	2,773 New	2,773 $297,000
Q3 2021 Nov 15, 2021	SELL	$80.98 - $109.47 $57,900 - $78,271	-715 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $59,187 - $72,215	715 New	715 $63 Million
Q1 2021 May 17, 2021	SELL	$90.71 - $108.28 $379,621 - $453,151	-4,185 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$92.08 - $124.48 $164,086 - $221,823	1,782 Added 74.16%	4,185 $469,000
Q3 2020 Nov 13, 2020	SELL	$66.45 - $92.7 $15,748 - $21,969	-237 Reduced 8.98%	2,403 $223 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $150,717 - $209,272	2,640 New	2,640 $206 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $40,797 - $69,722	-848 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$66.73 - $82.59 $56,587 - $70,036	848 New	848 $67,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.